¼¼°èÀÇ Ã¼¿ÜºÐºñ ±â´ÉºÎÀü(EPI) Ä¡·á ¹× Áø´Ü ½ÃÀå º¸°í¼­(2025³â)
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Global Market Report 2025
»óǰÄÚµå : 1686367
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,183,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,938,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,692,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ü¿ÜºÐºñ ±â´ÉºÎÀü(EPI) Ä¡·á ¹× Áø´Ü ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ °­·ÂÇÑ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â CAGR 7.8%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 83¾ï 2,000¸¸ ´Þ·¯·Î ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ ¼ºÀåÀº ¿ø°Ý ÀÇ·á ¹× ¿ø°Ý ¸ð´ÏÅ͸µ, µ¥ÀÌÅÍ ºÐ¼®°ú AI, ȯÀÚ ±³À° ¹× Áö¿ø, ±ÔÁ¦ º¯°æ ¹× »óȯ Á¤Ã¥¿¡ ±âÀÎÇϰí ÀÖ½À´Ï´Ù. ¿¹Ãø ±â°£ ÁÖ¿ä µ¿Çâ¿¡´Â °³º°È­ Ä¡·á Á¢±Ù¹ý, ½Å±Ô Ä¡·á¹ý °³¹ß, Àúħ½À Áø´Ü, °øµ¿ ÄÉ¾î ¸ðµ¨ µîÀÌ ÀÖ½À´Ï´Ù.

´ç´¢º´ÀÇ À¯º´·ü Áõ°¡´Â ÇâÈÄ Ã¼¿ÜºÐºñ ±â´ÉºÎÀü(EPI) Ä¡·á ¹× Áø´Ü ½ÃÀåÀÇ È®´ë¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ´ç´¢º´Àº Ç÷´ç »ó½Â(°íÇ÷´ç)À» Ư¡À¸·Î ÇÏ´Â ¸¸¼ºÁúȯÀ¸·Î ü³»¿¡¼­ Àν¶¸°ÀÌ ÃæºÐÈ÷ ºÐºñµÇÁö ¾Ê°Å³ª Àν¶¸°À» È¿°úÀûÀ¸·Î »ç¿ëÇÏÁö ¸øÇÏ´Â °ÍÀÌ ¿øÀÎÀÔ´Ï´Ù. ÃéÀå È¿¼Ò º¸Ãæ ¿ä¹ý(PERT)À» Æ÷ÇÔÇÑ EPI Ä¡·á´Â ´ç´¢º´ ¹× EPI ȯÀÚ ¸ðµÎ¿¡¼­ ¿µ¾ç Èí¼ö¸¦ ³ôÀÌ°í ´õ ³ªÀº Ç÷´ç Á¶ÀýÀ» Áö¿øÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2024³â 6¿ù ±¹¹Îº¸°Ç¼­ºñ½º(NHS England)´Â 2023³â ´ç´¢º´ ¿¹ºñ±ºÀ¸·Î Áø´Ü¹ÞÀº »ç¶÷ÀÇ ¼ö°¡ 2022³â 306¸¸ 5,825¸í¿¡¼­ 18% Áõ°¡ÇÏ¿© 361¸¸ 5,330¸íÀÌ µÇ¾ú´Ù°í º¸°íÇß½À´Ï´Ù. 40¼¼ ¹Ì¸¸¿¡¼­´Â ´ç´¢º´ ¿¹ºñ±ºÀÌ 2022³â 17¸¸ 3,166¸í¿¡¼­ 2023³â 21¸¸ 6,440¸íÀ¸·Î 25% °¡±îÀÌ Áõ°¡Çß½À´Ï´Ù. ÀÌ ´ç´¢º´ Àα¸ Áõ°¡°¡ EPI Ä¡·á ¹× Áø´Ü ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¼ÒÈ­±â ÁúȯÀÇ ±ÞÁõÀº ´ç¸éÇÑ Ã¼¿ÜºÐºñ ±â´ÉºÎÀü(EPI) Ä¡·á ¹× Áø´Ü ½ÃÀåÀÇ È®´ë¸¦ °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼ÒÈ­°ü Áúȯ¿¡´Â ¼ÒÈ­¸¦ °üÀåÇÏ´Â ±â°üÀ» Æ÷ÇÔÇÑ ¼ÒÈ­°ü¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ´Ù¾çÇÑ º´¼¼°¡ Æ÷ÇԵ˴ϴÙ. À§ÀåÁúȯ °ü¸®´Â È¿¼Ò ºÎÁ·À» ½ÃÁ¤Çϰí È¿°úÀûÀÎ ¿µ¾ç ¼ÒÈ­¸¦ ÃËÁøÇϴ ü¿ÜºÐºñ ±â´ÉºÎÀü(EPI) Ä¡·á ¹× Áø´Ü¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 6¿ù ÇöÀç ij³ª´Ù¿¡ º»ºÎ¸¦ µÐ ºñ¿µ¸®´Üü Crohn's and Colitis Canada´Â 2023³â¿¡´Â 32¸¸ 2,600¸í ÀÌ»óÀÇ Ä³³ª´ÙÀÎÀÌ ¿°Áõ¼º ÀåÁúȯ(IBD)À» ¾Î¾ÒÀ¸¸ç, Àα¸ÀÇ ¾à 0.82%¸¦ Â÷ÁöÇÑ °ÍÀ¸·Î Æò°¡Çß½À´Ï´Ù. IBDÀÇ À¯º´·üÀº ¾ÕÀ¸·Îµµ °è¼ÓµÉ °ÍÀ¸·Î ¿¹ÃøµÇ¾î 2035³â¿¡´Â ¾à 47¸¸ ¸íÀÇ Ä³³ª´ÙÀÎÀÌ IBD¿¡ ÀÌȯµÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â Àα¸ÀÇ ¾à 1.1%, Áï ±¹¹ÎÀÇ ¾à 91¸í Áß 1¸íÀÌ ÀÌȯÇÏ°Ô µË´Ï´Ù. ±× °á°ú ¼ÒÈ­±â ÁúȯÀÇ ÀÌȯÀ² Áõ°¡°¡ ü¿ÜºÐºñ ±â´ÉºÎÀü(EPI) Ä¡·á ¹× Áø´Ü ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ ¹× Àü·«

Á¦4Àå ½ÃÀå-±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, Äڷγª, ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼® ¹× Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ ¹× ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å· ¹× ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹® ¹× Àü·«

Á¦36Àå ºÎ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics pertain to the treatment of a condition where the pancreas fails to produce adequate digestive enzymes necessary for the effective breakdown and absorption of nutrients from food within the small intestine. The role of EPI diagnostics and therapeutics is pivotal in the identification and management of exocrine pancreatic insufficiency, facilitating individuals with EPI in attaining improved nutrient absorption and overall well-being.

The primary forms of treatments encompassed within exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics comprise nutritional management, pancreatic enzyme replacement therapy (PERT), and lifestyle adjustments. Nutritional management is a specialized healthcare approach utilizing nutrition and diet to address various medical and health conditions. Diverse diagnostic techniques are employed, including blood tests, magnetic resonance imaging (MRI), endoscopic ultrasonography (EUS), and computerized tomography (CT) scanning. Various types of medications, both generic and branded, are utilized, and these are distributed through a range of channels such as direct tender, retail pharmacy, third-party distributor, and others. These are availed by a diverse array of end users including hospitals, specialty clinics, homecare, diagnostic centers, research and academic institutes, among others.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market research report is one of a series of new reports from The Business Research Company that provides exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market statistics, including exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics industry global market size, regional shares, competitors with a exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market share, detailed exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market segments, market trends and opportunities and any further data you may need to thrive in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics industry. This exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market size has grown strongly in recent years. It will grow from $5.69 billion in 2024 to $6.17 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increased prevalence of underlying conditions, advancements in diagnostic tools, pharmaceutical developments, rising global healthcare access.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market size is expected to see strong growth in the next few years. It will grow to $8.32 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to telemedicine and remote monitoring, data analytics and ai, patient education and support, regulatory changes and reimbursement policies. Major trends in the forecast period include personalized treatment approaches, development of novel therapies, minimally invasive diagnostics, collaborative care models.

The growing prevalence of diabetes is anticipated to drive the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the future. Diabetes is a chronic condition characterized by elevated blood sugar levels (hyperglycemia), resulting from the body's inability to produce sufficient insulin or use the insulin effectively. EPI treatment, including pancreatic enzyme replacement therapy (PERT), can enhance nutrient absorption and support better glycemic control in individuals with both diabetes and EPI. For example, in June 2024, the National Health Service (NHS England) reported that the number of people diagnosed with pre-diabetes in 2023 increased to 3,615,330, an 18% rise from 3,065,825 in 2022. Among those under 40, pre-diabetes cases rose nearly 25%, from 173,166 in 2022 to 216,440 in 2023. This growing diabetic population is fueling the demand for EPI therapeutics and diagnostics.

The surge in cases of gastrointestinal disorders is projected to drive the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the foreseeable future. Gastrointestinal disorders encompass a range of medical conditions affecting the digestive tract, including the organs responsible for digestion. Managing gastrointestinal diseases relies significantly on exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics, which rectify enzyme deficiencies and promote effective nutrient digestion. For instance, as of June 2023, Crohn's and Colitis Canada, a non-profit organization based in Canada, estimated that over 322,600 Canadians were living with inflammatory bowel diseases (IBD) in 2023, constituting about 0.82% of the population. With the prevalence of IBD projected to persist, it is anticipated that approximately 470,000 Canadians will have IBD by 2035, roughly 1.1% of the population, or about 1 in every 91 individuals in the country. Consequently, the escalating incidence of gastrointestinal disorders is anticipated to be a driving force behind the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

Key players in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are increasingly forming strategic partnerships to integrate advanced technologies and broaden their market presence. A strategic partnership involves collaboration between two or more organizations, combining their resources, expertise, and efforts to reach shared objectives. For example, in February 2023, Codexis, Inc., a protein engineering firm based in the US, partnered with Nestle Health Science, a Swiss nutrition company, to announce the interim results of their Phase 1 clinical trial of CDX-7108, an investigational therapy for EPI. These promising results from the trial open the door for further research that could lead to improved treatment options for individuals affected by EPI.

In October 2022, DiaSorin SpA, an Italian biotechnology firm, acquired Luminex Corporation for $1.8 billion. This acquisition allows DiaSorin to bolster its presence in the U.S. market, expand its product portfolio, and establish long-term collaborations with biopharmaceutical companies. Luminex Corporation, based in the U.S., specializes in biological testing technologies, including those related to exocrine pancreatic insufficiency (EPI).

Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market consists of revenues earned by entities by providing dietary interventions and bile acid replacement therapy (BAR). The market value includes the value of related goods sold by the service provider or included within the service offering. The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market also includes sales of Creon, Zenpep and Ultresa. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for exocrine pancreatic insufficiency (epi) therapeutics and diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Characteristics

3. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Trends And Strategies

4. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Growth Analysis And Strategic Analysis Framework

6. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Segmentation

7. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Regional And Country Analysis

8. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

9. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

10. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

11. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

12. Australia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

13. Indonesia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

14. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

15. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

16. UK Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

17. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

18. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

19. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

20. Spain Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

21. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

22. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

23. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

24. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

25. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

26. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

27. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

28. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

29. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

30. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Landscape And Company Profiles

31. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Other Major And Innovative Companies

32. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

34. Recent Developments In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

35. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â